Merrimack Pharmaceuticals News

Merrimack Pharmaceuticals | 15-12G: Notice of termination of registration of a class of securities under Section 12(g) (and amendment thereto)

May 20 16:13 ET

Merrimack Pharmaceuticals | 10-Q: Q1 2024 Earnings Report

May 15 22:44 ET

Merrimack Pharmaceuticals | 25: Notification of the removal from listing and registration of matured, redeemed or retired securities (and amendment thereto)

May 10 16:49 ET

Merrimack Pharmaceuticals | 8-K: Current report

May 10 16:45 ET

Merrimack Pharmaceuticals | DEFA14A: Others

May 9 07:47 ET

Merrimack Pharmaceuticals | 8-K: Current report

May 9 07:47 ET

Merrimack Pharmaceuticals | DEFA14A: Others

Apr 30 17:28 ET

Merrimack Pharmaceuticals | 8-K: Current report

Apr 30 17:27 ET

Merrimack Pharmaceuticals | DEFR14A: Definitive proxy statement in connection with contested solicitations

Apr 1 16:36 ET

Merrimack Pharmaceuticals | DEFA14A: Others

Mar 27 17:05 ET

Merrimack Pharmaceuticals | 8-K: Current report

Mar 27 17:00 ET

Merrimack Pharmaceuticals | DEFA14A: Others

Mar 22 09:47 ET

Merrimack Pharmaceuticals | DEF 14A: Definitive information statements

Mar 21 16:58 ET

Merrimack Pharmaceuticals | 10-K/A: Annual report (Amendment)

Mar 21 16:52 ET

Merrimack Pharmaceuticals | 425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions

Mar 7 16:46 ET

Merrimack Pharmaceuticals | 8-K: Current report

Mar 7 16:41 ET

Merrimack Pharmaceuticals | 10-K: FY2023 Annual Report

Mar 7 16:22 ET

Merrimack Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-BlackRock, Inc.(4.99%)

Mar 7 12:36 ET

Merrimack Pharmaceuticals | PRE 14A: Preliminary proxy statements relating to merger or acquisition

Mar 5 16:52 ET

Merrimack Pharmaceuticals | SCHEDULE 13G: Others

Feb 22 16:50 ET